The effects of improved access to diabetes medications on risk of Alzheimer's disease and related dementias.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
HumansAlzheimer DiseaseHypoglycemic AgentsDementiaSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsFemaleAgedMaleMiddle AgedIncidenceHealth Services AccessibilityDiabetes MellitusDiabetes Mellitus, Type 2ADRDADRD preventionAlzheimer's diseaseAlzheimer's disease and related dementiasGLP1SGLT2access to prescription drugschronic disease managementdementiadementia preventiondiabetesdiabetes managementglucagon‐like peptide 1 receptor agonistssodium‐glucose cotransporter‐2 inhibitors
Come citare questo studio
Douglas Barthold, Julie Zissimopoulos, Anirban Basu, Bryan Tysinger. (2026). The effects of improved access to diabetes medications on risk of Alzheimer's disease and related dementias.. Alzheimer's & dementia : the journal of the Alzheimer's Association. DOI: 10.1002/alz.71794
Consulta la pubblicazione originale ↗